Browsing by Subject "Copy number variants"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Recurrent duplications of the annexin A1 gene (ANXA1) in autism spectrum disorders
    (Springer Nature, 2014-04-10) Correia, Catarina T.; Conceição, Inês C.; Oliveira, Bárbara; Coelho, Joana; Sousa, Inês; Sequeira, Ana F.; Almeida, Joana; Café, Cátia; Duque, Frederico; Mouga, Susana; Roberts, Wendy; Gao, Kun; Lowe, Jennifer K.; Thiruvahindrapuram, Bhooma; Walker, Susan; Marshall, Christian R.; Pinto, Dalila; Nurnberger, John I.; Scherer, Stephen W.; Geschwind, Daniel H.; Oliveira, Guiomar; Vicente, Astrid M.; Psychiatry, School of Medicine
    Background: Validating the potential pathogenicity of copy number variants (CNVs) identified in genome-wide studies of autism spectrum disorders (ASD) requires detailed assessment of case/control frequencies, inheritance patterns, clinical correlations, and functional impact. Here, we characterize a small recurrent duplication in the annexin A1 (ANXA1) gene, identified by the Autism Genome Project (AGP) study. Methods: From the AGP CNV genomic screen in 2,147 ASD individuals, we selected for characterization an ANXA1 gene duplication that was absent in 4,964 population-based controls. We further screened the duplication in a follow-up sample including 1,496 patients and 410 controls, and evaluated clinical correlations and family segregation. Sequencing of exonic/downstream ANXA1 regions was performed in 490 ASD patients for identification of additional variants. Results: The ANXA1 duplication, overlapping the last four exons and 3'UTR region, had an overall prevalence of 11/3,643 (0.30%) in unrelated ASD patients but was not identified in 5,374 controls. Duplication carriers presented no distinctive clinical phenotype. Family analysis showed neuropsychiatric deficits and ASD traits in multiple relatives carrying the duplication, suggestive of a complex genetic inheritance. Sequencing of exonic regions and the 3'UTR identified 11 novel changes, but no obvious variants with clinical significance. Conclusions: We provide multilevel evidence for a role of ANXA1 in ASD etiology. Given its important role as mediator of glucocorticoid function in a wide variety of brain processes, including neuroprotection, apoptosis, and control of the neuroendocrine system, the results add ANXA1 to the growing list of rare candidate genetic etiological factors for ASD.
  • Thumbnail Image
    Item
    Whole Genome Sequencing of Pedigrees With High Density of Substance Use and Psychiatric Disorders: A Meeting Report
    (Wiley, 2025) Hill, Shirley Y.; Edenberg, Howard J.; Corvin, Aiden; Thorgeirsson, Thorgeir; Below, Jennifer E.; Goldman, David; Leal, Suzanne; Almasy, Laura; Cox, Nancy J.; Daly, Mark; Neale, Benjamin; Vrieze, Scott; Zoghbi, Huda; Biochemistry and Molecular Biology, School of Medicine
    The National Institute of Drug Abuse convened a panel of scientists with expertise in substance use disorders (SUD) and genetic methodologies primarily to determine the feasibility of performing whole genome sequencing utilizing existing pedigree collections with a high density of SUD and psychiatric disorders. A major focus was on determining if there had been any successes in identifying genetic variants for complex traits in family-based designs. Such information could provide assurance that whole genome sequencing might provide significant pay-offs particularly in the pursuit of rare variants and copy number variants. An important goal was to discuss and evaluate optimal strategies for studying genetic variants in human samples. Specific topics were (a) to consider whether a smaller number of cases typically available in family studies versus the larger number available in biobanks can reveal unique information; (b) to identify potential gaps in information available in biobank data that might be supplemented with family data; (c) to consider the optimal SUD phenotypic definitions (e.g., quantity of use, problem-oriented) and data collection instruments (self-report or clinician administered) that are both practical and efficient to collect, and likely to provide important insights concerning prevention, intervention, and medication development. Conclusions reached by the panel included optimism about the successes that have occurred in the existing family studies ascertained to include densely affected pedigrees. Evaluation of methodologies led, overall, to a panel consensus that steps should be taken to utilize biobank collection in conjunction with family-based investigations for optimal variant discovery.